A Randomized, Double-blind, Multicenter Phase Iii Study To Evaluate The Long-term Efficacy And Safety Of Abx464 25 Mg Or 50 Mg Once Daily As A Maintenance Therapy In Subjects With Moderately To Severe

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Sasha Taleban
Sponsor
Abivax (France)
Unit
Medicine